Mohammed Al-Jumayli, MD, on a Digital Prehabilitation Model in Older Adults Undergoing Hepatobiliary Cancer Surgery
ASCO 2026
Mohammed Al-Jumayli, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses the effects of the use of a multimodal, digitally supported prehabilitation program among adults aged 65 years and older undergoing surgery for hepatobiliary cancer; the model was associated with favorable short-term functional performance signals and high levels of engagement (Abstract 12039).
Lucy Gilbert, MD, of McGill University Health Centre, discusses subgroup analyses from the ROSELLA study. Relacorilant plus nab-paclitaxel demonstrated a statistically and clinically significant overall survival benefit in patients with platinum-resistant ovarian cancer compared to a weekly taxane; subgroup analyses for overall survival showed a consistent benefit favoring the addition of relacorilant to nab-paclitaxel irrespective of prior taxane use (Abstract 5503).
The ASCO Post Staff
François-Clément Bidard, MD, PhD, of Institut Curie, presents final progression-free survival 2 findings from the phase III SERENA-6 trial, which investigated the efficacy of camizestrant, a selective estrogen receptor degrader (SERD), vs continued aromatase inhibition in patients with advanced breast cancer with emergent ESR1 mutations. Earlier reports from the trial showed improved progression-free survival with the SERD (Abstract LBA1007).
The ASCO Post Staff
Ghassan K. Abou-Alfa, MD, PhD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, presents efficacy and safety data from the randomized phase III EMERALD-3 trial, which evaluated tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization in patients with unresectable embolization-eligible hepatocellular carcinoma (LBA4000).
The ASCO Post Staff
Lauren Averett Byers, MD, of The University of Texas MD Anderson Cancer Center, describes data on ABBV-706—an investigational antibody-drug conjugate targeting SEZ6—alone or in combination with the anti–PD-1 monoclonal antibody budigalimab in patients with relapsed or refractory small cell lung cancer (SCLC) (Abstract 8008).
The ASCO Post Staff
Richard Cathomas, MD, of Cantonal Hospital Graubünden, reviews results from the primary analysis of SAKK 06/19, an open-label single arm phase II trial, which found that the combination of intravesical recombinant bacillus Calmette-Guérin (BCG) with atezolizumab, cisplatin, and gemcitabine was feasible and safe without unexpected toxicities and demonstrates promising efficacy in patients with muscle-invasive bladder cancer (MIBC) (Abstract 4503).
